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Abstract
We investigated the impact of olmesartan and temocapril on pancreatic islet beta-cells during
the development of diabetes mellitus using Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats.
Four-week-old male OLETF rats were fed standard chow (untreated:n5), or chow containing ei-
ther 0.005% olmesartan(n5) or 0.01% temocapril (n5) until being sacrificed at 35 weeks of age.
Pancreas sections were double-stained with anti-insulin and anti-glucagon antibodies. The per-
cent areas of beta-cells, alpha-cells and non-alpha-non-beta-cells were compared among groups.
In untreated OLETF rats, the fasting plasma glucose (FPG) level was elevated at the 18th week
and remained elevated until the 35th week. On the other hand, no significant elevation in FPG
levels was observed in olmesartan- or temocapril-treated rats. Pancreatic islets from olmesartan-
treated rats were significantly smaller in size as compared with those from untreated OLETF rats.
Furthermore, the average area occupied by beta-cells as a fraction of the total area of an individ-
ual islet was significantly higher in olmesartan- or temocapril-treated rats than that in untreated
OLETF rats. Olmesartan and temocapril both prevented the development of hyperglycemia, pos-
sibly through the prevention of islet beta-cell loss in spontaneously diabetic OLETF rats.
KEYWORDS: angiotensin II type-1 receptor blocker, angiotensin converting enzyme inhibitor,
pancreas, insulin secretion, Type 2 diabetes mellitus
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We investigated the impact of olmesartan and temocapril on pancreatic islet ｹ-cells during the devel-
opment of diabetes mellitus using Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats. Four-week-old 
male OLETF rats were fed standard chow (untreated: n＝5),  or chow containing either 0.005ｵ olm-
esartan (n＝5) or 0.01ｵ temocapril (n＝5) until being sacriﬁced at 35 weeks of age.  Pancreas sections 
were double-stained with anti-insulin and anti-glucagon antibodies.  The percent areas of ｹ-cells,  
ｸ-cells and non-ｸ-non-ｹ-cells were compared among groups.  In untreated OLETF rats,  the fasting 
plasma glucose (FPG) level was elevated at the 18th week and remained elevated until the 35th week.  
On the other hand,  no signiﬁcant elevation in FPG levels was observed in olmesartan- or temocapril-
treated rats.  Pancreatic islets from olmesartan-treated rats were signiﬁcantly smaller in size as com-
pared with those from untreated OLETF rats.  Furthermore,  the average area occupied by ｹ-cells as 
a fraction of the total area of an individual islet was signiﬁcantly higher in olmesartan- or temocapril-
treated rats than that in untreated OLETF rats.  Olmesartan and temocapril both prevented the devel-
opment of hyperglycemia,  possibly through the prevention of islet ｹ-cell loss in spontaneously diabetic 
OLETF rats.
Key words: angiotensin II type-1 receptor blocker,  angiotensin converting enzyme inhibitor,  pancreas,  insulin 
secretion,  Type 2 diabetes mellitus
n 1999,  an angiotensin-converting-enzyme 
inhibitor (ACEI),  captopril,  was for the ﬁrst 
time reported in a large scale clinical trial to poten-
tially decrease the incidence of new-onset Type 2 
diabetes mellitus (T2DM) as compared with conven-
tional antihypertensive therapy in patients with dia-
stolic hypertension [1].  Other ACEIs including 
ramipril,  enalapril and lisinopril,  as well as angio-
tensin II type-1 receptor (AT1) blockers (ARBs) such 
as losartan,  candesartan,  and valsartan,  have shown 
similar reductions of new-onset T2DM independent of 
their blood-pressure-lowering eﬀect in non-diabetic 
patients with hypertension or with heart failure in 
randomized clinical trials [2,  3].  Hence,  it is sug-
gested that the renin-angiotensin system (RAS) block-
ade with whichever ACEIs or ARBs could delay or 
prevent the onset of T2DM [4,  5].
　 The mechanisms by which ACEIs and/or ARBs 
attenuate the onset of T2DM remain to be elucidated,  
but they may involve both insulin secretion from pan-
creatic islet β-cells and insulin sensitivity at the 
peripheral tissues including skeletal muscles and adi-
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pocytes [2,  6,  7].  Initially,  much attention was paid 
to the improvement of insulin sensitivity by RAS 
blockade,  which is often seen in diabetic patients;  
however,  conﬂicting reports have mounted,  thus rais-
ing controversy over whether it counts as the preven-
tion of diabetes onset [4].  Recently,  local RAS in the 
pancreas has been discovered [8,  9],  and has been 
postulated to play crucial roles in the pathogenesis of 
diabetes in animal models [10ﾝ13].
　 OLETF rats are an established model of T2DM,  
characterized by obesity and insulin resistance [14,  
15].  The morphological changes in the OLETF ratsʼ 
pancreatic tissues during the course of the develop-
ment of diabetes have been documented in detail [14ﾝ
17].  In brief,  the islets show a typical appearance of 
“peripheral α-cells and central β-cells” at the 10th 
week [16],  and some islets start to enlarge and 
develop new blood vessels and ducts in the periphery 
of the islet at the 20th week,  followed by the destruc-
tion of the “peripheral α-cells and central β-cells” 
appearance by ﬁbrous tissues at the 40th week.  Such 
changes in pancreatic histology were not observed in 
non-diabetic LETO rats until 40 weeks,  and hence are 
considered to be alterations speciﬁc to diabetic ani-
mals [17].  Recently,  Ko et al.  reported that ramipril 
suppressed islet ﬁbrosis in OLETF rats [10].
　 Olmesartan and temocapril,  similarly to other 
ARBs and ACEIs,  respectively,  have been shown to 
possess actions beneﬁcial for the improvement of glu-
cose intolerance [18ﾝ21].  Therefore,  it is expected 
that these agents could also reduce the incidence of the 
new onset of T2DM in future clinical trials.  In the 
present study,  we examined the impact of olmesartan 
and temocapril on the pathogenesis of diabetes in 
OLETF rats,  focusing on the diabetogenic alterations 
of pancreas morphology.
Materials and Methods
　 Antibodies and chemicals. Guinea pig poly-
clonal antibody against porcine insulin antibody was 
purchased from Thermo Shandon (Pittsburgh,  PA,  
USA),  and rabbit polyclonal antibody against porcine 
glucagon was purchased from Zymed Laboratory 
(South San Francisco,  CA,  USA).  Rabbit polyclonal 
anti-AT1 receptor antibody was kindly provided by 
Prof.  Rakugi (Osaka University) [22].  Olmesartan 
and temocapril were provided by Sankyo Pharma-
ceutical Company.
　 Animals and experimental design. Animals 
were cared for and treated in accordance with the 
guidelines of the Animal Use and Care Committee at 
Okayama University and the Guide for the Care and 
Use of Laboratory Animals published by the US 
National Institutes of Health (NIH publication No.  85
ﾝ23,  revised 1985).  OLETF rats were kindly pro-
vided by the Tokushima Research Institute (Otsuka 
Pharmaceutical,  Tokushima,  Japan).  Fifteen male,  4 
week-old OLETF rats were housed singly with food 
and water ad libitum; speciﬁcally,  they were fed 
standard rat chow containing 5ｵ fat (Oriental Yeast,  
Tokyo,  Japan).  When the rats were 8 weeks of age,  
they were randomly assigned to one of 3 groups that 
were fed one of the following: standard chow 
(untreated,  n＝5),  or chow containing either 0.005ｵ 
olmesartan (olmesartan-treated,  n＝5) or 0.01ｵ 
temocapril (temocapril-treated,  n＝5).  The doses of 
these agents were the same as those used by Kim et al.  
[23] in order to generate compatible suppressor 
eﬀects.
　 The following clinical parameters were determined 
at weeks 5,  9,  13,  18,  22,  26,  30,  and 35 in all 
animals: body weight,  blood pressure,  fasting plasma 
glucose (FPG),  fasting plasma insulin,  serum fruc-
tosamine,  24-h collected urine volume,  and 24-h uri-
nary excretion of C-peptide.  The pancreases were 
dissected out at the 35th week.  Each pancreas was 
ﬁxed in 10ｵ formalin and embedded in paraﬃn.  For 
histopathological examination,  4μm sections were 
stained with Masson-Trichrome and subjected to the 
immunostaining procedures described below.
　 Insulin-glucagon immunostaining. Sections 
were ﬁrst incubated with polyclonal anti-insulin anti-
body followed by anti-glucagon antibody at room tem-
perature for 2h each.  Secondary antibodies,  namely 
biotin-conjugated goat anti-guinea-pig IgG and biotin-
conjugated goat anti-rabbit IgG (Vector Labs,  
Burlingame,  CA,  USA),  were used as the anti-insu-
lin and anti-glucagon antibodies,  respectively.  The 
sections were labeled with avidin-biotin-complex 
(Vectastain Elite ABC kit,  Vector Labs) for glucagon,  
or with ABC-alkaline phosphatase (ABC-AP) proce-
dures (Vectastain Elite ABC-AP kit,  Vector Labs) 
for insulin.  Sections were visualized with Vector Red 
(Vectastain) and diaminobenzidine (DAB) and counter-
stained with Mayerʼs hematoxylin.
36 Acta Med.  Okayama　Vol.  63,  No.  1Kaihara et al.
2
Acta Medica Okayama, Vol. 63 [2009], Iss. 1, Art. 5
http://escholarship.lib.okayama-u.ac.jp/amo/vol63/iss1/5
　 AT1 receptor immunostaining. The section 
serial to that used for insulin-glucagon double staining 
was subjected to AT1 receptor immunostaining.  Poly-
clonal anti-AT1 antibodies were labeled with the ABC 
procedure and visualized with DAB.  Sections were 
microwaved at 500W for 10min to activate the epitope 
immunogenicity.
　 Morphological measurement. Using the 
image analysis software OPTIMAS 6.5 (Medi-
acybernetics,  Silver Spring,  MD,  USA),  the isletʼs 
total area,  anti-glucagon antibody-stained (α-cell) area 
and anti-insulin antibody-stained (β-cell) area were 
outlined.  In the present study,  we deﬁned the sub-
traction of the α-cell area and the β-cell area from the 
total islet area as the non-α-non-β-cell area.  The area 
occupied by the β-cells,  α-cells and non-α-non-β-cells 
in an individual islet was calculated.
　 Statistical analysis. Values are expressed as 
the means ± SE.  Statistical analyses were performed 
using Stat View 5.0 (ABACUS Concepts,  Berkeley,  
CA,  USA).  Diﬀerences between untreated OLETF 
rats and olmesartan-treated or temocapril-treated 
animals were analyzed using an unpaired Studentʼs 
t-test.  A p＜0.05 was considered to be signiﬁcant.
Results
　 Clinical features. The time courses of body 
weight,  systolic blood pressure,  and FPG values are 
shown in Fig.  1.  There were no signiﬁcant diﬀer-
ences in body weight among the groups,  though 
temocapril-treated rats tended to gain less weight than 
animals in the other groups (Fig.  1A,  at 35th week,  
temocapril; 556±25g, untreated; 651±9g, p＝0.0518). 
Systolic blood pressures in olmesartan-treated and in 
temocapril-treated rats were signiﬁcantly lower than 
in untreated OLETF rats (Fig.  1B,  at 13th week,  
olmesartan; 122±2mmHg,  temocapril; 123±2mmHg,  
untreated; 139±2mmHg,  p＜0.05 for both vs.  
untreated).  FPG levels in untreated OLETF rats 
gradually increased to over 140mg/dl at the 18th 
week and stayed above that level until the animals 
were sacriﬁced.  Contrarily,  the FPG levels in either 
treatment group never exceeded 140mg/dl (Fig.  1C).  
FPG values in temocapril-treated rats stayed at sig-
niﬁcantly lower levels than those in untreated OLETF 
rats throughout the study period,  while the decrease 
in levels in olmesartan-treated rats reached statistical 
signiﬁcance solely at the 26th week.  There were no 
signiﬁcant diﬀerences between olmesartan- and temo-
capril-treated rats in either systolic blood pressures 
or FPG values throughout the experiment (Figs.  1B,  
1C).
　 Serum fructosamine, fasting plasma insulin 
and 24-h urinary C-peptide. Levels of serum 
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Fig. 1　 Changes of body weight (A),  systolic blood pressure (B),  
and fasting plasma glucose levels (C) in untreated (open circle),  
olmesartan-treated (closed circle),  and temocapril-treated (closed 
box) OLETF rats.
#p＜0.05 notes olmesartan-treated versus untreated.  ＊p＜0.05 
notes temocapril-treated versus untreated.
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fructosamine,  fasting plasma insulin,  and 24-h col-
lected urinary C-peptide at the time of sacriﬁce are 
shown in Table 1.  Both insulin and C-peptide levels in 
olmesartan- or temocapril-treated rats tended to be 
higher than those in untreated OLETF rats; however,  
statistically signiﬁcant diﬀerences were not observed 
among the groups.
　 Pathohistological alterations in pancreatic 
islets at 35th week. In Fig.  2A,  the pancreas of 
a non-diabetic LETO rat at 35 weeks of age is shown 
as a reference for the typical appearance of “periph-
eral α-cells and central β-cells”.  In the present study,  
we observed various alterations in the appearance of 
islets (representatives are shown in Figs.  2Bﾝ2D),  as 
well as in their size and number (summarized in Fig.  
2F).  The islet size was distributed widely,  ranging 
from small (2,500ﾝ10,000μm2) to huge (＞70,000μm2).  
Huge islets were occasionally found only in untreated 
OLETF rats,  and there was a signiﬁcant diﬀerence in 
average islet size between untreated and olmesartan-
treated rats.  Small islets were seen in all groups.  
There were many tiny islets (＜2,500μm2) in all 
groups,  although we have ignored them in the current 
study for technical reasons.  It is notable that small 
islets and tiny islets were found most frequently in 
untreated islets,  suggesting islet generation (data not 
shown).
　 Huge islets contained noticeable areas of non-α
-non-β-cells with disrupted arrangements of “periph-
eral α-cells” (Figs.  2B,  2F).  Mid-range-sized islets 
(10,000ﾝ70,000μm2) were found in the pancreas in all 
groups with a similar incidence (Fig.  2F); however,  
their appearances diﬀered markedly between the 
untreated and treated groups.  Namely,  the islets from 
untreated OLETF rats appeared to be down-sized 
copies of huge islets,  while those from olmesartan- or 
temocapril-treated rats showed the “peripheral α-cells 
and central β-cells” appearance (Figs.  2C,  2D).  The 
average areas occupied by β-cells,  α-cells and non-α
-non-β-cells in individual islets are shown in Fig.  2F.  
The occupancy rates of β-cells and α-cells in either 
olmesartan- or temocapril-treated rats were signiﬁ-
cantly higher than those in untreated OLETF rats 
(Fig.  2F).  The area occupied by non-α-non-β-cells 
consisted mainly of connective tissues and microves-
sels under Masson-Trichrome stain (data not shown).
　 AT1 receptor localization in islets. In the 
serial section analysis,  AT1 receptors were recog-
nized in the rat pancreas,  predominantly in acinar 
cells and to a lesser extent in islets (Fig.  3B).  There 
were no diﬀerences in the cellular distribution and 
intensity of AT1 receptor immunostaining among 
experimental groups (data not shown).  Figs.  3C and 
3D demonstrated relatively strong AT1 receptor 
staining in areas occupied by β-cells and non-α-non-β
-cells in islets but not in areas occupied by α-cells.
Discussion
　 Male OLETF rats are a useful model of T2DM,  
characterized by obesity and insulin resistance start-
ing around 16 weeks of age [17].  Simultaneously,  
hyperinsulinemia develops in order to cope with 
peripheral insulin resistance,  accompanied by morpho-
logical changes in the pancreas including islet enlarge-
ment and an increase in the number of islets and β
-cells.  FPG starts to rise at around 18 to 24 weeks,  
reﬂecting the limitation of β-cellsʼ compensation.  
Meanwhile,  connective tissues emerge and proliferate 
in islets,  separating them in clusters to develop a 
“nodular” appearance.  By the age of 40 weeks,  severe 
hyperglycemia is seen as a consequence of deterio-
rated insulin secretion and the ﬁbrotic destruction of 
islets [14ﾝ17].
　 Pancreases from untreated animals in the present 
study showed the above-mentioned diabetogenic mor-
phology at the 35th week (Figs.  2B,  2F).  Olmesar tan 
or temocapril treatment clearly attenuated the mor-
phological alterations both in islet size and islet num-
ber (Figs.  2C,  2D,  2E).  Since islet enlargement 
requires an increase in the β-cell number,  there may 
be β-cell generation,  duplication or diﬀerentiation.  
Furthermore,  the decreasing trend in the number of 
38 Acta Med.  Okayama　Vol.  63,  No.  1Kaihara et al.
Table 1　 Levels of fructosamine,  fasting plasma insulin and 
24-h urine C-peptide of untreated,  olmesartan-treated,  or temo-
capril-treated OLETF rats at 35 weeks
untreated olmesartan temocapril
Fructosamine (μmol/l) 217±88 223±9 192±4 　
Plasma insulin (ng/ml) 1.2±0.2 2.0±0.1 1.8±0.1
24-h urine C-peptide
(ng/mgCr) 2.3±0.05 2.8±0.1 3.8±0.23
Values are means±SE.  No signiﬁcant diﬀerences were observed 
among groups.
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Fig. 2　 Immunohistological visualization of β-cells (red) and α-cells (brown) in pancreatic islets and morphological analysis in untreated,  
olmesartan-treated and temocapril-treated OLETF rats at 35 weeks.
A,  Typical appearance of pancreas at 35 weeks  of age from a non-diabetic LETO rat displaying peripheral α-cells (brown) regularly sur-
rounding the central cluster of β-cells (red) (served as reference).  B-D,  Representative appearances of huge islets from an untreated 
OLETF rat (B),  a moderately enlarged islet from an olmesartan-treated OLETF rat (C),  and a moderately enlarged islet from a temocapril-
treated OLETF rat (D).  E,  Islet size in untreated OLETF rats was distributed widely from tiny (less than 2,500μm2) to huge (larger than 
70,000μm2),  whereas that in olmesartan-treated OLETF rats never exceeded 40,000μm2.  ＊ denotes signiﬁcant (p＜0.05) diﬀerence in aver-
age islet size between untreated and olmesartan-treated rats.  F,  Averaged area occupied by β-cells (closed),  alpha-cells (stripe),  and 
non-α-non-β-cellsʼ area (open),  ＊ p＜0.05 vs.  untreated,  ＊＊ p＜0.01 vs.  untreated,  ## p＜0.01 vs.  untreated OLETF rats.  scale 
bar: 100μm
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islets (Fig.  2E),  in particular the number of tiny 
islets (data not shown),  in treated rats,  prompted us 
to speculate that islet generation occurring in 
untreated OLETF rats might have been prevented by 
RAS inhibitors.
　 FPG levels in animals treated with RAS inhibitors 
were signiﬁcantly lower than those in untreated ani-
mals from the 18th week to the 35th week (Fig.  1C).  
Since no signiﬁcant diﬀerences were observed in lev-
els of serum fructosamine,  fasting plasma insulin,  or 
urinary C-peptide among groups,  post-fed plasma 
glucose levels might not have diﬀered greatly between 
treated rats and untreated rats.  Indeed,  urinary 
C-peptide levels were within normal range in all 
groups (Table 1).  Thus,  we have demonstrated the 
prevention of the very early steps of diabetogenesis in 
OLETF rats.
　 It is apparent that olmesartan and/or temocapril 
inhibited connective tissue growth in pancreatic islets 
(Fig.  2F).  Both agents have been shown to mediate 
antiﬁbrotic actions in animal models of cardiovascular 
and kidney diseases where local RAS plays important 
roles [23ﾝ25].  Recently,  Ko et al.  suggested that 
ramipril potentially prevented the islet destruction by 
ﬁbrosis in OLETF rats.  Here,  we have demonstrated 
that both olmesartan and temocapril also prevented 
islet destruction,  supporting the emerging concept 
that pancreas RAS might play a crucial role in the 
diabetogenic process in T2DM [4,  6].  The precise 
mechanisms remain to be elucidated; however,  they 
may include the blockade of angiotensin II action on 
cellular proliferation,  apoptosis,  TGF-β activation 
40 Acta Med.  Okayama　Vol.  63,  No.  1Kaihara et al.
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Fig. 3　 AT1 receptor localization in rat pancreatic islets.
A and C,  Double staining with anti-insulin (red) and anti-glucagon (brown) antibodies.  B and D,  AT1 receptors (brown) were immunohis-
tologically recognized in the pancreas,  predominantly in the acinar cells,  to a less extent in islet β-cells (black arrow head),  and not at all 
in α-cells (white arrow head).  A and B are serial sections,  and C and D are magniﬁed images of A and B.  Scale bar: 100μm (A,  
B); 10μm (C,  D)
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[10],  and reactive oxygen generation [26].  In addi-
tion,  a direct action of zofenoprilat and enalaprilat,  
ACEIs,  on pancreatic β-cell protection has been sug-
gested [27].  We have demonstrated the predominant 
distribution of AT1 receptors on β-cells in islets.  
Further studies are needed to elucidate whether these 
AT1 receptors play a role in β-cell duplication,  which 
is possibly involved in islet enlargement.
　 In conclusion,  both olmesartan and temocapril 
protected pancreatic islets,  and β-cells in particular,  
from the morphological deterioration of diabetogene-
sis.  AT1 receptors expressed on β-cells may be 
involved in the mechanism underlying such favorable 
actions of RAS inhibitors.
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